Clinical trials: Residual
Gastric Residuals Assessment, Prematurity
Does Routine Assessment of Gastric Residuals in Preterm Neonates Influence Time Taken to Reach Full Enteral Feeding?
The study aims to compare routine assessment of gastric residuals versus no assessment of residuals in preterm neonates with respect to time taken for achieving full enteral feeding and the incidence of possible complications…
- Conditions
- Gastric Residuals Assessment, Prematurity, Sepsis Newborn, Necrotizing Enterocolitis of Newborn
- Trial name
- GRASS (NCT03111329)
- Testing
- No aspiration of gastric residuals
- Where
- 2 sites in Czechia, Ireland
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Institute for the Care of Mother and Child, Prague, Czech Republic
Consciousness Disorder, Cognitive Impairment
Neurophysiological Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness
Identify potential markers of recovery through event-related potentials (ERPs) in the evolution of altered consciousness with potential ability to discriminate between different conditions of altered state of consciousness.
- Trial name
- NCT05802524
- Testing
- Neurowave Group
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
D010051, Ovarian Cancer
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indicators (QIs) in advanced ovarian cancer surgery.
- Conditions
- D010051, Ovarian Cancer, Advanced-stage Ovarian Cancer, FIGO Stages III and IV
- Trial name
- retroESGO ov1 (NCT07567573)
- Testing
- Preoperative Evaluations, Cytoreductive Surgery, Perioperative Management
- Where
- Belgium
- Volunteers
- 11,383 people
- Sponsor
- European Society of Gynaecological Oncology
Lentigo Maligna
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
This is a prospective, longitudinal, uncontrolled study with follow-up for 5 years.Patients having undergone surgical excision of lentigo maligna (LM) or lentigo maligna melanoma (LMM) will be invited to this study.
- Trial name
- NCT01088737
- Testing
- Imiquimod
- Where
- 2 sites in Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Graz
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Colorectal Cancer
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer.
- Trial name
- MRD (NCT05210283)
- Testing
- MRD
- Where
- 32 sites in United States, Canada
- Volunteers
- 1,017 people
- Sponsor
- Exact Sciences Corporation
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
Asthma
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate
This study aims to determine whether an extra virgin olive oil-based water (EVOOW) mixture removes more fluticasone propionate (FP) from the mouth than water alone.
- Trial name
- EVOOW (NCT07664527)
- Testing
- Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Shoulder Pain
A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain
A pulmonary recruitment maneuver at the end of surgery reduced shoulder pain as well as nausea and vomiting after laparoscopic surgery.
- Trial name
- NCT00575237
- Testing
- Recruitment manouver
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Phelps, Paul, M.D.
Gastric Adenocarcinoma
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
Gastric cancer is one of the most prevalent and lethal malignancies in China. The majority of patients are diagnosed at the locally advanced stage.
- Trial name
- NCT07034742
- Testing
- Intraperitoneal chemotherapy PLUS systemic chemotherapy
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Diurnal Residual Limb Fluid Volume Fluctuation
Accommodating for Residual Limb Fluid Volume Change
The purpose of this study is to quantify residual limb fluid volume changes between morning and afternoon hours, and to determine if fluid volume change is correlated with activity.
- Trial name
- AM-PM (NCT02124876)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
CLL
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%).
- Trial name
- NCT04639362
- Testing
- ibrutinib, venetoclax, obinutuzumab, ibrutinib, venetoclax
- Where
- 27 sites in Denmark, Netherlands
- Volunteers
- 85 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Brain and Central Nervous System Tumors
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor.
- Trial name
- NCT00752323
- Testing
- aminolevulinic acid, Surgical Resection
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Andrew Sloan, MD
Peritoneal Dialysis Complication, Residual Kidney Function
Incremental PD With Single Icodextrin Exchange
Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD). Subjects: Seventy-two incident PD patients.
- Conditions
- Peritoneal Dialysis Complication, Residual Kidney Function, Survival, Health-related Quality of Life
- Trial name
- NCT06119373
- Testing
- Single daily icodextrin exchange, Conventional PD group
- Volunteers
- 72 people
- Sponsor
- RenJi Hospital
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
- Trial name
- NCT02477670
- Testing
- AVP-786
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
- Trial name
- NCT06536959
- Testing
- PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing 302 Hospital
Paediatric Surgery
Residual Torsional Deformity in Pediatric Genu Varum After Coronal Plane Deformity Correction by 8 Plate Hemi Epiphysiodesis.
This study is to evaluate the residual torsional deformity in pediatric Genu Varum after coronal plane deformity correction by 8 plate hemi epiphysiodesis.
- Trial name
- NCT05334862
- Testing
- 8 plate hemiepiphysiodesis
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Assiut University
Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD)
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS).
- Trial name
- NCT06886074
- Testing
- Short course of blinatumomab
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Hand Hygiene
Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method
To evaluate the residual antimicrobial effectiveness of one test product when tested using a modification of the methodology of the standardized ASTM E115-11 (2017)
- Trial name
- NCT04654182
- Testing
- Chlorhexidine Gluconate
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Molnlycke Health Care AB
Residual Neuromuscular Block (TOF-ratio of 0.2)
Sugammadex and Neostigmine at Residual Neuromuscular Blockade
This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.
- Trial name
- SUNDRO20 (NCT01006720)
- Testing
- Sugammadex, Neostigmine, Saline
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Technical University of Munich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.